NO20061837L - Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser - Google Patents
Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaserInfo
- Publication number
- NO20061837L NO20061837L NO20061837A NO20061837A NO20061837L NO 20061837 L NO20061837 L NO 20061837L NO 20061837 A NO20061837 A NO 20061837A NO 20061837 A NO20061837 A NO 20061837A NO 20061837 L NO20061837 L NO 20061837L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- matrix metalloproteinases
- inhibitors
- acid derivatives
- wound healing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10344936A DE10344936A1 (de) | 2003-09-27 | 2003-09-27 | Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen |
PCT/EP2004/010248 WO2005030728A1 (de) | 2003-09-27 | 2004-09-14 | Bicyclische iminosäurederivate als inhibitoren von matrix-metalloproteinasen |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061837L true NO20061837L (no) | 2006-06-01 |
Family
ID=34353126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061837A NO20061837L (no) | 2003-09-27 | 2006-04-26 | Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1670766B1 (ja) |
JP (1) | JP4861179B2 (ja) |
KR (1) | KR20060086367A (ja) |
CN (1) | CN1856478B (ja) |
AR (1) | AR046165A1 (ja) |
AT (1) | ATE550327T1 (ja) |
AU (1) | AU2004275937A1 (ja) |
BR (1) | BRPI0414594A (ja) |
CA (1) | CA2539731A1 (ja) |
DE (1) | DE10344936A1 (ja) |
IL (1) | IL174040A0 (ja) |
MA (1) | MA28075A1 (ja) |
ME (1) | MEP33008A (ja) |
MX (1) | MXPA06002927A (ja) |
MY (1) | MY139830A (ja) |
NO (1) | NO20061837L (ja) |
NZ (1) | NZ546158A (ja) |
PE (1) | PE20050432A1 (ja) |
RS (1) | RS20060194A (ja) |
RU (1) | RU2335494C2 (ja) |
TW (1) | TW200520755A (ja) |
UY (1) | UY28539A1 (ja) |
WO (1) | WO2005030728A1 (ja) |
ZA (1) | ZA200601501B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
DE102005002500A1 (de) | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen |
DE102005015040A1 (de) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
ES2658964T3 (es) | 2007-08-03 | 2018-03-13 | Nucitec S.A. De C.V. | Composiciones y métodos para el tratamiento y la prevención de la osteoartritis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201303B (ja) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
FR2701480B1 (fr) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
PL186869B1 (pl) | 1995-11-13 | 2004-03-31 | Hoechst Ag | Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie |
KR20000035917A (ko) * | 1996-08-28 | 2000-06-26 | 데이비드 엠 모이어 | 1,4-헤테로고리성 메탈로프로테아제 저해제 |
ID22849A (id) * | 1997-01-23 | 1999-12-09 | Hoffmann La Roche | Penghambat-penghambat sulmafida-metaloprotease |
DE10300015A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen |
DE102004031620A1 (de) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/de not_active Withdrawn
-
2004
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/de active Application Filing
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 EP EP04786944A patent/EP1670766B1/de not_active Expired - Lifetime
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/ja not_active Expired - Fee Related
- 2004-09-14 AT AT04786944T patent/ATE550327T1/de active
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/es active IP Right Grant
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/ko not_active Application Discontinuation
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/pt not_active IP Right Cessation
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/sr unknown
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/xx unknown
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/zh not_active Expired - Fee Related
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/ru not_active IP Right Cessation
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/es not_active Application Discontinuation
- 2004-09-23 AR ARP040103437A patent/AR046165A1/es not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/zh unknown
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/es unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/fr unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1670766A1 (de) | 2006-06-21 |
TW200520755A (en) | 2005-07-01 |
CA2539731A1 (en) | 2005-04-07 |
WO2005030728A1 (de) | 2005-04-07 |
IL174040A0 (en) | 2006-08-01 |
UY28539A1 (es) | 2005-04-29 |
ATE550327T1 (de) | 2012-04-15 |
CN1856478B (zh) | 2010-05-26 |
RU2335494C2 (ru) | 2008-10-10 |
AR046165A1 (es) | 2005-11-30 |
RU2006114352A (ru) | 2006-08-27 |
CN1856478A (zh) | 2006-11-01 |
MA28075A1 (fr) | 2006-08-01 |
EP1670766B1 (de) | 2012-03-21 |
RS20060194A (en) | 2008-08-07 |
JP2007506690A (ja) | 2007-03-22 |
JP4861179B2 (ja) | 2012-01-25 |
DE10344936A1 (de) | 2005-04-21 |
MXPA06002927A (es) | 2006-06-14 |
MEP33008A (en) | 2010-10-10 |
PE20050432A1 (es) | 2005-07-21 |
AU2004275937A1 (en) | 2005-04-07 |
BRPI0414594A (pt) | 2006-11-07 |
MY139830A (en) | 2009-10-30 |
NZ546158A (en) | 2008-11-28 |
KR20060086367A (ko) | 2006-07-31 |
ZA200601501B (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0220187D0 (en) | Organic compounds | |
GB0121033D0 (en) | Organic compounds | |
HK1089659A1 (en) | Bicyclic inhibitors of mek and methods of synthesis thereof | |
ATE331718T1 (de) | Spirosubstituierte pyrrolopyrimidine | |
WO2005090333A8 (en) | 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | |
WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
NO20044038L (no) | Glutaminylbaserte DRIV-inhibitorer | |
WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
IL187438A0 (en) | Pyrrolopyridine derivatives and pharmaceutical compositions containing the same | |
WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
PL367821A1 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | |
IL172773A0 (en) | Formulations for the treatment of arhritis conditions | |
WO2005073236A3 (de) | Thieno-iminosäure-derivate als inhibitoren von matrix-metalloproteinasen | |
WO2003065987A3 (en) | Granzyme b inhibitors | |
NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
NO20061837L (no) | Bicykliske iminosyrederivater anvendt som inhibitorer av matriksmetalloproteinaser | |
WO2006042103A3 (en) | Reversible inhibitors of cathepsin b | |
WO2003028721A3 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
AU7385398A (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
NO983511D0 (no) | Difenylstilbener som pro-legemidler for COX-2-inhibitorer | |
MY128242A (en) | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf | |
BRPI0606493A2 (pt) | derivados de tetrahidrofurano para uso como inibidores das metaloproteinases da matriz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |